HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment.
The clearance followed a successful appeal of a previous not substantially equivalent determination, the company said in a Dec. 9 news release. The system uses a three-axis signal capture method to generate a 12-lead ECG without traditional electrode cables.
HeartBeam plans a limited commercial launch in early 2026, focusing on concierge and preventive cardiology practices. The initial rollout will support real-world testing and inform broader distribution.
The company’s future initiatives include a wearable 12-lead ECG patch and an AI-enabled platform trained on longitudinal patient data. HeartBeam said the clearance supports its efforts to expand access to diagnostic ECG data outside traditional care settings.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
